Nanomicellar formulations for sustained drug delivery: strategies and underlying principles R Trivedi, UB Kompella Nanomedicine 5 (3), 485-505, 2010 | 389 | 2010 |
Recent advances in ophthalmic drug delivery UB Kompella, RS Kadam, VHL Lee Therapeutic delivery 1 (3), 435-456, 2010 | 346 | 2010 |
Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. VH Lee, A Yamamoto, UB Kompella Critical reviews in therapeutic drug carrier systems 8 (2), 91, 1991 | 339 | 1991 |
Subconjunctival nano-and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression UB Kompella, N Bandi, SP Ayalasomayajula Investigative ophthalmology & visual science 44 (3), 1192-1201, 2003 | 335 | 2003 |
Microfluidic devices for drug delivery systems and drug screening S Damiati, UB Kompella, SA Damiati, R Kodzius Genes 9 (2), 103, 2018 | 327 | 2018 |
Periocular routes for retinal drug delivery S Raghava, M Hammond, UB Kompella Expert opinion on drug delivery 1 (1), 99-114, 2004 | 327 | 2004 |
Presenilin 1 maintains lysosomal Ca2+ homeostasis via TRPML1 by regulating vATPase-mediated lysosome acidification JH Lee, MK McBrayer, DM Wolfe, LJ Haslett, A Kumar, Y Sato, PPY Lie, ... Cell reports 12 (9), 1430-1444, 2015 | 325 | 2015 |
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications HF Edelhauser, CL Rowe-Rendleman, MR Robinson, DG Dawson, ... Investigative ophthalmology & visual science 51 (11), 5403-5420, 2010 | 313 | 2010 |
Nanoparticle technology for drug delivery RB Gupta, UB Kompella Taylor & Francis Group, LLc, 2006 | 298 | 2006 |
Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? S Mathison, R Nagilla, UB Kompella Journal of drug targeting 5 (6), 415-441, 1998 | 290 | 1998 |
Nanomedicines for back of the eye drug delivery, gene delivery, and imaging UB Kompella, AC Amrite, RP Ravi, SA Durazo Progress in retinal and eye research 36, 172-198, 2013 | 282 | 2013 |
Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur L Zhang, DL Parsons, C Navarre, UB Kompella Journal of Controlled Release 85 (1-3), 73-81, 2002 | 250 | 2002 |
Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV SR Singh, HE Grossniklaus, SJ Kang, HF Edelhauser, BK Ambati, ... Gene therapy 16 (5), 645-659, 2009 | 242 | 2009 |
Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration AC Amrite, UB Kompella Journal of pharmacy and pharmacology 57 (12), 1555-1563, 2005 | 240 | 2005 |
Preparation of drug delivery systems using supercritical fluid technology UB Kompella, K Koushik Critical Reviews™ in Therapeutic Drug Carrier Systems 18 (2), 2001 | 228 | 2001 |
Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration H Yang, P Tyagi, RS Kadam, CA Holden, UB Kompella ACS nano 6 (9), 7595-7606, 2012 | 214 | 2012 |
Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage AC Amrite, SP Ayalasomayajula, NPS Cheruvu, UB Kompella Investigative ophthalmology & visual science 47 (3), 1149-1160, 2006 | 202 | 2006 |
Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat … SP Ayalasomayajula, UB Kompella European journal of pharmacology 458 (3), 283-289, 2003 | 202 | 2003 |
Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration AC Amrite, HF Edelhauser, SR Singh, UB Kompella Molecular vision 14, 150, 2008 | 185 | 2008 |
Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model SP Ayalasomayajula, UB Kompella European journal of pharmacology 511 (2-3), 191-198, 2005 | 177 | 2005 |